Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK: Neoadjuvant Toripalimab, Chemotherapy, and SBRT for Undifferentiated Pleomorphic Sarcoma
NCT07817095Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in undifferentiated pleomorphic sarcoma (UPS), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT07817095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817095.